Undecimal Bio
Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.
$18MSeed
Lead4C
4BIO Capital
Activity from announced rounds
Activity in this selectionOct 15, 2026 · Biotech · Jul 18, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- 3 All roles disclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $96.4M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAptadir Therapeutics
RNA therapeutics designed to restore expression of silenced genes
€40MSeed
LeadCloverleaf Bio
Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.
$33MSeed
Lead